Want to see CRVS full AI Analyst Report?
CRVS Stock Chart & Stats
$13.07
-$0.15(-1.15%)
At close: 4:00 PM EDT
$13.07
-$0.15(-1.15%)
Day’s Range― - ―
52-Week Range$4.05 - $26.95
Previous Close$13.39
Volume846.90K
Average Volume (3M)1.25M
Market Cap
$1.12B
Enterprise Value$1.08K
Total Cash (Recent Filing)$215.23M
Total Debt (Recent Filing)$728.00K
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Oct 29, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding84,090,420
10 Day Avg. Volume965,200
30 Day Avg. Volume1,250,599
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.60Price Target Upside141.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.68
Revenue Forecast (FY)-$200.00K
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA ~$215M cash balance with an explicit runway into Q2 2028 materially reduces near-term financing pressure and gives management flexibility to execute multiple clinical programs. This durable liquidity buffer supports trial enrollment, regulatory interactions, and strategic optionality over the next 18+ months.
Promising Phase I AD Efficacy And SafetyRobust, durable clinical signals and a clean safety profile in Phase I provide mechanistic validation for soquelitinib and a differentiated clinical positioning versus systemic immunosuppressants. If replicated in later trials, this strengthens the drug's commercial prospects and de-risks development trajectory over the medium term.
Low Leverage And Stronger CapitalizationVery low debt and a large equity base after recent financings materially improve solvency and strategic optionality. This balance sheet strength supports continued R&D investment, potential partnerships or M&A, and reduces bankruptcy/dilution risk compared with highly leveraged peers over the coming quarters.
Bears Say
Sustained Negative Cash FlowPersistent and sizable negative operating and free cash flow increases reliance on capital markets to fund operations. Even with current runway, continued burn at these levels raises dilution and financing risk, which can constrain strategic choices and shareholder value over the medium term.
Rising R&D Spend And Widening LossesAccelerating R&D investment is necessary to advance programs but materially increases operating losses and cash consumption. Without revenue, higher expense intensity elevates the probability of future financings and dilution, pressuring long-term per-share economics unless clinical success offsets costs.
Clinical/regulatory Execution RiskKey programs face binary clinical and regulatory milestones (e.g., interim futility, enrollment-driven timelines). Such event-driven risks can permanently terminate development or delay commercialization, making future cash needs and value realization highly contingent on successful execution.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $4.05 and its highest was $26.95 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is $1.12B.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.159 by -$0.031.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.19.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 84,090,420 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.159. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.60 (141.78% Upside)
$31.60 (141.78% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $333.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
175.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
325.98%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
CRVS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive development picture driven by a strong cash position, promising Phase 1 atopic dermatitis efficacy and safety signals, multiple planned trials across indications, and defined near-term catalysts (Angel cohort data, SEERA-1 topline, PTCL interim). These positives are tempered by substantially higher R&D spend and widening net losses, increased stock-based compensation, and clinical/regulatory execution risks (including a futility analysis and reliance on partner timelines). On balance the clinical progress and cash runway meaningfully outweigh the financial and execution risks in the near term.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$31.60
▲(141.78% Upside)
Technical Analysis
Ownership Overview
13.84% Insiders
12.11% Mutual Funds
2.61% Other Institutional Investors
57.27% Public Companies and
Individual Investors